(Pancreatic Cancer) Effectiveness of Ibrutinib + Gemcitabine + nab-Paclitaxel?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
The RESOLVE/PCYC-1137 Phase III trial evaluated the combination of Ibrutinib (Imbruvica) + Gemcitabine + nab-Paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Primary evaluation metrics were progression-free survival and overall survival, with secondary metrics including objective response rate and safety. The trial assessed whether adding Ibrutinib to standard gemcitabine/nab-paclitaxel chemotherapy could improve outcomes in this difficult-to-treat cancer.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4